HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD. Hubei Biocause Pharmaceutical Co., Ltd. Share Price
Equities
000627
CNE000000F48
Life & Health Insurance
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.16 CNY | +0.47% |
|
-5.68% | -23.94% |
| Sales 2022 | 49.31B 6.81B 568B | Sales 2023 | 48.28B 6.67B 556B | Capitalization | 14.03B 1.94B 162B |
|---|---|---|---|---|---|
| Net income 2022 | 274M 37.84M 3.16B | Net income 2023 | -652M -90.04M -7.51B | EV / Sales 2022 | 0.35 x |
| Net Debt 2022 | 1.76B 243M 20.28B | Net cash position 2023 | 2.73B 378M 31.5B | EV / Sales 2023 | 0.23 x |
| P/E ratio 2022 |
52.7
x | P/E ratio 2023 |
-21.8
x | Employees | 1,765 |
| Yield 2022 |
3.48% | Yield 2023 |
-
| Free-Float | 31.71% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.47% | ||
| 1 week | -5.68% | ||
| 1 month | -9.24% | ||
| 3 months | -21.17% | ||
| 6 months | -29.18% | ||
| Current year | -23.94% |
1 week
2.13
2.27
1 month
2.132.49
Current year
2.113.08
1 year
2.113.91
3 years
2.113.91
5 years
2.117.95
10 years
2.1117.30
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Xia Zhou
CEO | Chief Executive Officer | 52 | 26/20/26 |
Jian Qiang Shen
CHM | Chairman | 52 | 01/96/01 |
Da Li Chen
DFI | Director of Finance/CFO | 57 | 26/20/26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Qian Liu
CHM | Chairman | 61 | 11/15/11 |
Yunhua Xiao
BRD | Director/Board Member | 62 | 01/03/01 |
Da Li Chen
DFI | Director of Finance/CFO | 57 | 26/20/26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 2.16 | +0.47% | 21,303,200 |
| 30/24/30 | 2.15 | -2.71% | 34,669,570 |
| 29/24/29 | 2.21 | -0.90% | 25,668,800 |
| 28/24/28 | 2.23 | -1.76% | 24,156,860 |
| 27/24/27 | 2.27 | -0.87% | 31,571,300 |
End-of-day quote Shenzhen S.E., May 31, 2024
More quotes
Hubei Biocause Pharmaceutical Co.,Ltd. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The Company is also involved in pharmaceutical business and chemical business. The Companyâs products include polypropylene and Ibuprofen. The Company distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.
Sector
Life & Health Insurance
Calendar
02/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.94% | 1.47B | |
| +12.07% | 78.88B | |
| +9.44% | 51.46B | |
| +8.93% | 51.07B | |
| +20.90% | 46.59B | |
| +16.04% | 43.21B | |
| +23.53% | 39.69B | |
| -0.60% | 29.1B | |
| -6.79% | 27.94B | |
| -15.80% | 26.05B |
- Stock Market
- Equities
- 000627 Stock
